Drug Development Infrastructure Supporting the Research Community in Medication Repurposing for Substance Use Disorders
Forecasted
NIDA seeks to support shared drug-development infrastructure to help academic and biotech researchers repurpose medications for substance use disorders and advance them toward clinical development.
Funder: National Institutes of Health
Due Dates (Anticipated): June 2027 (Estimated application deadline)
Funding Amounts: $2,500,000 estimated total program funding; 1 expected cooperative agreement; no cost sharing or matching required
Summary: Supports drug-development infrastructure serving academic and biotech investigators repurposing and repositioning medications for substance use disorders.
Description
The National Institute on Drug Abuse (NIDA), part of the National Institutes of Health, seeks to support a dynamic, adaptable drug-development infrastructure that accelerates medication repurposing and repositioning for substance use disorders (SUDs). The infrastructure will provide academic and biotech investigators with coordinated scientific expertise, shared resources, and tailored support across the drug-development continuum.
Capabilities may span discovery, target and assay validation, preclinical and translational development, pharmacology, toxicology, clinical protocol development, and patient engagement. Support may also include Target Product Profile development, intellectual property strategy, regulatory guidance, and market-access planning. The infrastructure will engage the research community through outreach, proposal solicitation, and structured project selection, supporting user-led projects across a broad range of SUD indications. Its goal is to advance promising therapeutics toward clinical development and potential market access.
